We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation (COBALT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02431988
Recruitment Status : Completed
First Posted : May 1, 2015
Last Update Posted : May 26, 2022
Information provided by (Responsible Party):
University College, London

Brief Summary:
The purpose of this study is to administer novel cluster of differentiation antigen 19 (CD19) specific Chimeric Antigen Receptor T-cells (CAR19 T-cells) to patients with relapsed or resistant Diffuse Large B Cell Lymphoma (DLBCL) to assess the safety and efficacy of this strategy as a bridge to allogeneic transplantation.

Condition or disease Intervention/treatment Phase
Diffuse Large B-Cell Lymphoma Procedure: Leukapheresis Drug: Cyclophosphamide Drug: Fludarabine Biological: CAR19 T-Cells Phase 1

Detailed Description:

Patients with Diffuse Large B Cell Lymphoma (DLBCL) resistant to or relapsing following rituximab-containing chemotherapy regimens have a poor prognosis. Patients may receive salvage chemotherapy and possibly an autologous stem cell transplant (auto-SCT). A proportion of these patients, however, will not respond to the chemotherapy or may relapse after the auto-SCT and therefore require novel treatment options. Such patients may benefit from an allogeneic stem cell transplantation (allo-STC).

In this study the investigators aim to administer CAR19 T-cells to act as a bridge to the transplant strategy. Specifically, (1) the feasibility of generating CD19 specific Chimeric Antigen Receptor T-cells called CAR19 T-cells, (2) the safety of administering the CD19 CAR T-cells in this setting, (3) how well the CAR19 T-cells engraft and (4) to evaluate how effective these cells are as a bridge to allogeneic transplantation.

Following informed consent and registration to the trial, patients will undergo an unstimulated leucapheresis for generation of the CAR19 T cells. Whilst the cells are being generated, patients will proceed with a further cycle of standard salvage (recommended ifosfamide, epirubicin and etoposide (i.e. the IVE regime), and should not receive rituximab. Patients will receive pre-conditioning with intravenous fludarabine and cyclophosphamide prior to infusion of a single dose of CAR-modified T-cells. An escalating dose protocol will be employed to identify a minimum effective dose of CAR19 T-cells.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation
Actual Study Start Date : June 2016
Actual Primary Completion Date : February 2, 2020
Actual Study Completion Date : March 21, 2022

Arm Intervention/treatment
Experimental: CAR19 T-cells

Patients will receive a single infusion of CAR19 T-cells following standard pre-conditioning with cyclophosphamide and fludarabine.

The CAR19 T-cells are to be administered on day 0.

Procedure: Leukapheresis
Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.

Drug: Cyclophosphamide
Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).

Drug: Fludarabine
Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).

Biological: CAR19 T-Cells

The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.

Three dose cohorts are planned:

  • Dose Level 1: 2x105 CAR19 T-cells/kg
  • Dose Level 2: 1x106 CAR19 T-cells/kg
  • Dose Level 3: 5x106 CAR19 T-cells/kg
Other Name: CD19 specific Chimeric Antigen Receptor T-cells

Primary Outcome Measures :
  1. Feasibility of adequate leucapheresis collection and generation of CAR19 T cells. [ Time Frame: 1 month ]
    The number of CAR19 T cells successfully manufactured as a fraction of the number of patients undergoing leukapheresis (all patients registered).

  2. Toxicity evaluation following CAR19 T-cell administration. [ Time Frame: 1 year ]
    Toxicity will be examined for each patient receiving CAR19 T cells, using the maximum grade for each toxicity type, all summarized as number of patients with adverse events.

  3. Efficacy of CAR19 T-cells. [ Time Frame: 1 year ]
    Efficacy will be defined as the number of patients that meet the clinical complete responders criteria.

Secondary Outcome Measures :
  1. CAR19 T-cell engraftment [ Time Frame: 1 year ]
    1. Engraftment, expansion and persistence of CAR19 T-cells. Detection of any level of CAR19 expression in circulating T cells (ie PBMC) by quantitative polymerase chain reaction (qPCR) and flow cytometry following infusion.

  2. B cell compartment [ Time Frame: 1 year ]
    2. Depletion of B cell compartment. The percentage reduction from baseline. Absolute B cell numbers measured by flow of PBMC (cells/ul) .

  3. Cytokine profile [ Time Frame: 1 year ]

    3. Timing and magnitude of cytokine release. Data on timing (kinetic of change) as the mean (or median) amount of cytokine (pg/ml) over a number of days post-infusion. Using the individual patient data, the mean (or median) time to peak value can be obtained.

    Magnitude - kinetic and peak of cytokine levels, notably Tumour Necrosis Factor-alpha (TNF-a), Interleukin- 6 (IL-6) and Interferon-gamma (IFN-g) (pg/ml), can be plotted for each patient, as means (or medians).

  4. Clinical complete response [ Time Frame: 1 month ]
    4. Clinical response evaluated using standard PET-CT criteria at day 28 compared to baseline scan. Proportion of patients with complete response will be calculated.

  5. Eligibility to allogeneic transplantation [ Time Frame: 1-3 years ]
    5. Number of patients proceeding to allogeneic transplantation out of all patients registered to the trial, and also only for those who received CAR19 T cells.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 16-65 years
  2. Confirmed diagnosis of CD19+ DLBCL
  3. Primary resistant or relapsed disease failing to achieve metabolic Complete Response (CR) to 1st line salvage, or relapse post autograft failing to achieve metabolic CR following a single further cycle of salvage
  4. Potential allogeneic transplant candidate
  5. Agreement to have a pregnancy test, use adequate contraception for 12 months post-CAR19 T-cell infusion
  6. Karnofsky performance status >60
  7. Written informed consent

Exclusion Criteria:

  1. Women who are pregnant or lactating
  2. Prior allogeneic transplantation
  3. Progressive disease following most recent salvage prior to planned leucapheresis (those with mixed response are eligible)
  4. Prior history of ischaemic heart disease, dysrhythmias, abnormal electrocardiogram (ECG)(Left Bundle Branch Block (LBBB)), Multiple Gated Acquisition (MUGA) left ventricular ejection fraction (LVEF) <40%
  5. Exclusions for proceeding to allogeneic transplantation (active hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV); liver function test (LFT) >3 x upper limit of normal (ULN); Creatinine Clearance (CrCl) <40 ml/min; or other comorbidity that precludes transplantation)
  6. Known central nervous system (CNS) involvement or cerebral vascular accident (CVA) within prior 3 months
  7. Patients receiving corticosteroids at a dose of > 10mg prednisolone per day (or equivalent)
  8. Use of rituximab within the last 2 months prior to CAR19 T-cell infusion
  9. Active autoimmune disease requiring immunosuppression
  10. Life expectancy <3 months
  11. Known allergy to albumin or dimethylsulfoxide (DMSO)
  12. Any contraindication to the administration and use of ifosfamide, epirubicin, etoposide, fludarabine and cyclophosphamide.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02431988

Layout table for location information
United Kingdom
University College London Hospital
London, United Kingdom
Sponsors and Collaborators
University College, London
Layout table for investigator information
Study Chair: Karl Peggs University College, London
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT02431988    
Other Study ID Numbers: UCL/14/0385
2015-000348-40 ( EudraCT Number )
First Posted: May 1, 2015    Key Record Dates
Last Update Posted: May 26, 2022
Last Verified: May 2022
Keywords provided by University College, London:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Large B-Cell, Diffuse
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists